biosynthetic human insulin

These three structural changes and formulation with zinc result in a prolonged action when compared with biosynthetic human insulin.

Prior to the introduction of biosynthetic human insulin, insulin derived from sharks was widely used in Japan.

In 1980, U.S. biotech company Genentech developed biosynthetic human insulin.

This explains the reluctance of many clinicians in the UK to change patients from porcine to semi-synthetic or biosynthetic human insulin.

Examples are the blood-production stimulating protein erythropoetin, or the growth-stimulating hormone named (simply) "growth hormone" or biosynthetic human insulin and its analogues.

Humulin is synthesized in a laboratory strain of Escherichia coli bacteria which has been genetically altered with recombinant DNA to produce biosynthetic human insulin.

Partnering with Genentech founded by Swanson, Boyer and Eli Lilly and Company went on in 1982 to sell the first commercially available biosynthetic human insulin under the brand name Humulin.